These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

134 related items for PubMed ID: 10384364

  • 1. Use of topical recombinant human platelet-derived growth factor-BB (becaplermin) in healing of chronic mixed arteriovenous lower extremity diabetic ulcers.
    Miller MS.
    J Foot Ankle Surg; 1999; 38(3):227-31. PubMed ID: 10384364
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and safety of a topical gel formulation of recombinant human platelet-derived growth factor-BB (becaplermin) in patients with chronic neuropathic diabetic ulcers. A phase III randomized placebo-controlled double-blind study.
    Wieman TJ, Smiell JM, Su Y.
    Diabetes Care; 1998 May; 21(5):822-7. PubMed ID: 9589248
    [Abstract] [Full Text] [Related]

  • 3. Recombinant human platelet-derived growth factor-BB (becaplermin) for healing chronic lower extremity diabetic ulcers: an open-label clinical evaluation of efficacy.
    Embil JM, Papp K, Sibbald G, Tousignant J, Smiell JM, Wong B, Lau CY.
    Wound Repair Regen; 2000 May; 8(3):162-8. PubMed ID: 10886806
    [Abstract] [Full Text] [Related]

  • 4. Becaplermin: recombinant platelet derived growth factor, a new treatment for healing diabetic foot ulcers.
    Nagai MK, Embil JM.
    Expert Opin Biol Ther; 2002 Feb; 2(2):211-8. PubMed ID: 11849120
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of becaplermin (recombinant human platelet-derived growth factor-BB) in patients with nonhealing, lower extremity diabetic ulcers: a combined analysis of four randomized studies.
    Smiell JM, Wieman TJ, Steed DL, Perry BH, Sampson AR, Schwab BH.
    Wound Repair Regen; 1999 Feb; 7(5):335-46. PubMed ID: 10564562
    [Abstract] [Full Text] [Related]

  • 6. Treatment of chronic ulcers in the lower extremities with topical becaplermin gel .01%: a multicenter open-label study.
    Guzman-Gardearzabal E, Leyva-Bohorquez G, Salas-Colín S, Paz-Janeiro JL, Alvarado-Ruiz R, García-Salazar R.
    Adv Ther; 2000 Feb; 17(4):184-9. PubMed ID: 11185057
    [Abstract] [Full Text] [Related]

  • 7. Use of Regranex gel for diabetic foot ulcers.
    Piascik P.
    J Am Pharm Assoc (Wash); 1998 Feb; 38(5):628-30. PubMed ID: 9782698
    [No Abstract] [Full Text] [Related]

  • 8. Becaplermin gel in the treatment of pressure ulcers: a phase II randomized, double-blind, placebo-controlled study.
    Rees RS, Robson MC, Smiell JM, Perry BH.
    Wound Repair Regen; 1999 Feb; 7(3):141-7. PubMed ID: 10417749
    [Abstract] [Full Text] [Related]

  • 9. Becaplermin gel (PDGF-BB) as topical wound therapy. Plastic Surgery Educational Foundation DATA Committee.
    Ladin D.
    Plast Reconstr Surg; 2000 Mar; 105(3):1230-1. PubMed ID: 10724287
    [Abstract] [Full Text] [Related]

  • 10. Clinical efficacy of becaplermin (rhPDGF-BB) gel. Becaplermin Gel Studies Group.
    Wieman TJ.
    Am J Surg; 1998 Aug; 176(2A Suppl):74S-79S. PubMed ID: 9777976
    [Abstract] [Full Text] [Related]

  • 11. [Approval for recombinant growth factor. Since January 2000, patients with diabetic foot ulcers can be treated with the growth factor becaplermin (Regranex), manufactured with genetic technology].
    Fruhstorfer B.
    Internist (Berl); 2000 Jan; 41(1):A38. PubMed ID: 10712088
    [No Abstract] [Full Text] [Related]

  • 12. [Becaplermin gel (Regranex gel)].
    Senet P.
    Ann Dermatol Venereol; 2004 Apr; 131(4):351-8. PubMed ID: 15258509
    [Abstract] [Full Text] [Related]

  • 13. Clinical safety of becaplermin (rhPDGF-BB) gel. Becaplermin Studies Group.
    Smiell JM.
    Am J Surg; 1998 Aug; 176(2A Suppl):68S-73S. PubMed ID: 9777975
    [Abstract] [Full Text] [Related]

  • 14. Effects of chronic wound fluid on the structure and biological activity of becaplermin (rhPDGF-BB) and becaplermin gel.
    Castronuovo JJ, Ghobrial I, Giusti AM, Rudolph S, Smiell JM.
    Am J Surg; 1998 Aug; 176(2A Suppl):61S-67S. PubMed ID: 9777974
    [Abstract] [Full Text] [Related]

  • 15. The cost-effectiveness of treating diabetic lower extremity ulcers with becaplermin (Regranex): a core model with an application using Swedish cost data.
    Persson U, Willis M, Odegaard K, Apelqvist J.
    Value Health; 2000 Aug; 3 Suppl 1():39-46. PubMed ID: 16464208
    [Abstract] [Full Text] [Related]

  • 16. Becaplermin gel in the treatment of diabetic neuropathic foot ulcers.
    Papanas N, Maltezos E.
    Clin Interv Aging; 2008 Aug; 3(2):233-40. PubMed ID: 18686746
    [Abstract] [Full Text] [Related]

  • 17. Randomized clinical trial comparing OASIS Wound Matrix to Regranex Gel for diabetic ulcers.
    Niezgoda JA, Van Gils CC, Frykberg RG, Hodde JP.
    Adv Skin Wound Care; 2005 Jun; 18(5 Pt 1):258-66. PubMed ID: 15942317
    [Abstract] [Full Text] [Related]

  • 18. The future of recombinant growth factors in wound healing.
    Robson MC, Mustoe TA, Hunt TK.
    Am J Surg; 1998 Aug; 176(2A Suppl):80S-82S. PubMed ID: 9777977
    [Abstract] [Full Text] [Related]

  • 19. Preclinical promise of becaplermin (rhPDGF-BB) in wound healing.
    LeGrand EK.
    Am J Surg; 1998 Aug; 176(2A Suppl):48S-54S. PubMed ID: 9777972
    [Abstract] [Full Text] [Related]

  • 20. Cost effectiveness of Becaplermin in the treatment of diabetic foot ulcers in four European countries.
    Ghatnekar O, Persson U, Willis M, Odegaard K.
    Pharmacoeconomics; 2001 Aug; 19(7):767-78. PubMed ID: 11548912
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.